Advertisement
Collaboration › Details
Servier–McDermott Will & Emery: legal services, 201612 advisor for license option agreem of Servier for Effi-7 with OSE Immunotherapeutics
McDermott Will & Emery. (1/6/17). "Press Release: McDermott Will & Emery Advised Servier in Its License Option Agreement with OSE Immunotherapeutics". Paris.
International law firm McDermott Will & Emery advised French-based Servier, an international pharmaceutical company, in its license option agreement with OSE Immunotherapeutics on the exclusive worldwide rights for the development and commercialization of the Effi-7 product. Effi-7 is a monoclonal immunomodulatory antibody.
OSE Immunotherapeutics is eligible to receive up to €272 million upon the exercise of a two-steps option license. These steps will enable the development of Effi-7 up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease.
The McDermott team advising on the transaction comprised of Paris-based partners Emmanuelle Trombe and Anthony Paronneau, along with associates Raphaëlle Monjou and Louise Aberg.
McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.
About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.
Related Professionals
Louise Aberg
Associate Paris
Raphaëlle Monjou
Associate Paris
Anthony Paronneau
Partner Paris
Emmanuelle Trombe
Partner Paris
Related Experience
Life Sciences
France
Licensing & Collaborative Arrangements
Record changed: 2018-08-21 |
Advertisement
More documents for Servier (Group)
- [1] Owkin. (10/17/23). "Press Release: Servier Partners with Owkin with the Aim of Discovering and Developing AI-driven Precision Therapeutics"....
- [2] Aqemia SAS. (1/9/23). "Press Release: Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology". Paris....
- [3] Aqemia SAS. (12/16/21). "Press Release: Aqemia and Servier Announce AI and Quantum Physics-drive Drug Discovery Collaboration in Immuno-oncology". Paris....
- [4] Servier. (6/16/21). "Press Release: Servier and PRISM BioLab Enter Drug Discovery Collaboration for a Novel Target". Paris & Tokyo....
- [5] MiNA Therapeutics Ltd.. (1/21/21). "Press Release: Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases". Paris & London....
- [6] Cytokinetics, Inc.. (12/23/20). "Press Release: Cytokinetics Regains European Rights to Omecamtiv Mecarbil". South San Francisco, CA....
- [7] Servier. (12/21/20). "Press Release: Servier to Acquire Agios Pharmaceuticals’ Oncology Business". Paris & Boston, MA....
- [8] Cytokinetics, Inc.. (11/23/20). "Press Release: Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 from Amgen". South San Francisco, CA....
- [9] Galapagos N.V.. (10/15/20). "Press Release: Galapagos and Servier Report Topline Results for ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086 in Knee Osteoarthritis Patients". Mechelen & Paris....
- [10] Servier. (10/6/20). "Press Release: The Servier Group Accelerates Its Digital Transformation and Has Named Virginie Dominguez as Chief Digital Officer". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top